PHB1P9: A Drug Target / Disease Biomarker (G100289414)

Target Name: PHB1P9

NCBI ID: G100289414

PHB1P9

Other Name(s): PHB1 pseudogene 9 | PHBP9 | Prohibitin pseudogene 9

PHB1P9: A Drug Target / Disease Biomarker

PHB1P9, also known as 尾-hydroxy-尾-methylbutyrate (HMB), is a drug target and a potential biomarker for several diseases, including cancer, obesity, and neurodegenerative disorders. Its unique structure, which consists of a 尾-hydroxy ring and a 尾-methyl group, makes it an attractive target for small molecules that can modulate its activity.

PHB1P9 has been shown to have a wide range of biological activities. For example, it has been shown to promote the growth inhibition of cancer cells, and to cause regression of cancer-induced cachexiation in animals. It has also been shown to reduce the body weight and body fat in obese rats, and to improve the body composition in these animals. In addition, PHB1P9 has been shown to protect against neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases, and to improve cognitive function in animal models of these disorders.

The unique structure of PHB1P9 makes it a difficult target for small molecules. However, several studies have identified compounds that can interact with its 尾-hydroxy ring and 尾-methyl group. These compounds include, but are not limited to, 尾-hydroxy-尾-methylbutyrate (HMB), 尾-hydroxy-尾-methylbutyrate amide (HMB-伪), and 尾-hydroxy-尾-methylbutyrate ethyl ester (HMB-尾).

尾-hydroxy-尾-methylbutyrate (HMB) is one of the most well-studied compounds that can interact with PHB1P9. HMB is a weak acid that can be converted to its 尾-hydroxy form by excretion in the urine. HMB has been shown to inhibit the activity of PHB1P9, and to cause regression of cancer-induced cachexiation in animals. In addition, HMB has been shown to reduce the body weight and body fat in obese rats, and to improve the body composition in these animals.

Another compound that has been shown to interact with PHB1P9 is 尾-hydroxy-尾-methylbutyrate amide (HMB-伪). HMB-伪 is a more potent inhibitor of PHB1P9 than HMB, and has been shown to be more effective in promoting regression of cancer-induced cachexiation in animals.

In addition to its interaction with PHB1P9, HMB has also been shown to have a variety of other biological activities. For example, it has been shown to promote the growth inhibition of cancer cells, and to cause regression of cancer-induced cachexiation in animals. It has also been shown to reduce inflammation in animal models of chronic inflammation, and to improve immune function in these models. In addition, HMB has been shown to protect against neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases, and to improve cognitive function in animal models of these disorders.

The potential of PHB1P9 as a drug target or biomarker is its ability to interact with a wide range of biological processes, including cancer growth, obesity, and neurodegenerative disorders. Its unique structure, which consists of a 尾-hydroxy ring and a 尾-methyl group, makes it an attractive target for small molecules that can modulate its activity. While further research is needed to fully understand its potential, PHB1P9 is a promising compound that may be useful in the development of new treatments for a variety of diseases.

Protein Name: PHB1 Pseudogene 9

The "PHB1P9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PHB1P9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets